Back

eIF4E and Ezrin cooperate in pseudopods to drive a localized migratory translation program in acute myeloid leukemia

Kraljacic, B.; Martinez, L. M.; Retiz, A.; Perron, S.; Shi, N.; Embree, C. M.; Yip, W.; Trujillo-Alonso, V.; Chu Carty, M.; Lassman, E.; Alilovic, K.; Carreno, S.; Roboz, G. J.; Guzman, M. L.; Borden, K. L. B.

2026-02-23 cancer biology
10.64898/2026.02.21.707190 bioRxiv
Show abstract

Aggressive subtypes of acute myeloid leukemia (AML) are characterized by increased migratory behavior and poor prognosis prioritizing the need for uncovering relevant mechanisms. While attributed to transcriptional changes, these AMLs manifest dysregulated eIF4E implicating disrupted mRNA metabolism. Here, we observed in AML mouse models, patient specimens, and cell lines that eIF4E drives motility, colonization, engraftment and AML progression. AML cells migrate utilizing Ezrin-positive pseudopods. Unexpectedly, we discovered that eIF4E interacts with Ezrin, that these physically associated factors are required and cooperated to drive an on-demand translation program in pseudopods for motility. Indeed, pseudopods were sites of eIF4E- and Ezrin-dependent translation by implementing the first method to directly mark active ribosomes in situ (Visualizing Translation Activity using RiboLace, VISTA-R). Biochemically, Ezrin bound eIF4E, ribosomal components, and mRNAs consistent with our observed Ezrin-dependent modulation of protein production. This unprecedented physical coupling of motility and translation provisions migratory sites to sustain AML progression. Highlights- eIF4E reduction impairs AML cell motility and disease progression - eIF4E-dependent motility requires Ezrin - Ezrin binds eIF4E, transcripts encoding motility factors and active ribosomes - VISTA-R enabled visualization of active ribosomes and translationally active pseudopods (T-PODs) - T-PODs provide novel on-demand localized translation to sustain mobility at migratory sites Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=142 SRC="FIGDIR/small/707190v2_ufig1.gif" ALT="Figure 1"> View larger version (41K): org.highwire.dtl.DTLVardef@164f191org.highwire.dtl.DTLVardef@2f8928org.highwire.dtl.DTLVardef@d5ad7forg.highwire.dtl.DTLVardef@719a69_HPS_FORMAT_FIGEXP M_FIG C_FIG

Matching journals

The top 10 journals account for 50% of the predicted probability mass.

1
eLife
5422 papers in training set
Top 2%
14.8%
2
Cell Reports
1338 papers in training set
Top 4%
8.4%
3
iScience
1063 papers in training set
Top 2%
4.9%
4
Oncogene
76 papers in training set
Top 0.3%
4.3%
5
Scientific Reports
3102 papers in training set
Top 29%
4.2%
6
Cells
232 papers in training set
Top 0.6%
3.7%
7
Blood Advances
54 papers in training set
Top 0.4%
3.6%
8
Frontiers in Physiology
93 papers in training set
Top 1%
3.1%
9
Nature Communications
4913 papers in training set
Top 44%
2.6%
10
Experimental Hematology
11 papers in training set
Top 0.1%
2.4%
50% of probability mass above
11
Haematologica
24 papers in training set
Top 0.2%
2.4%
12
International Journal of Molecular Sciences
453 papers in training set
Top 8%
1.7%
13
Computational and Structural Biotechnology Journal
216 papers in training set
Top 4%
1.7%
14
Molecular Cancer Research
42 papers in training set
Top 0.3%
1.7%
15
Communications Biology
886 papers in training set
Top 9%
1.7%
16
Nucleic Acids Research
1128 papers in training set
Top 11%
1.7%
17
Cancers
200 papers in training set
Top 3%
1.7%
18
Clinical Cancer Research
58 papers in training set
Top 1%
1.7%
19
Life Science Alliance
263 papers in training set
Top 0.4%
1.5%
20
Cell Communication and Signaling
35 papers in training set
Top 0.5%
1.5%
21
PLOS ONE
4510 papers in training set
Top 60%
1.2%
22
Blood
67 papers in training set
Top 1%
1.0%
23
Computers in Biology and Medicine
120 papers in training set
Top 4%
0.9%
24
Leukemia
39 papers in training set
Top 0.7%
0.8%
25
Biomedicine & Pharmacotherapy
43 papers in training set
Top 1%
0.7%
26
Frontiers in Cell and Developmental Biology
218 papers in training set
Top 9%
0.7%
27
Genome Medicine
154 papers in training set
Top 8%
0.7%
28
Science Advances
1098 papers in training set
Top 31%
0.7%
29
Cancer Discovery
61 papers in training set
Top 2%
0.7%
30
Heliyon
146 papers in training set
Top 7%
0.7%